NRAS Exon 3 Mutation
Associated Genetic Biomarkers
NRAS Exon 3 Mutation is present in 1.64% of AACR GENIE cases, with cutaneous melanoma, melanoma, colon adenocarcinoma, lung adenocarcinoma, and thyroid gland papillary carcinoma having the greatest prevalence .
NRAS Exon 3 Mutation serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains NRAS Exon 3 Mutation as an inclusion criterion, 1 is phase 3 (1 open).
Trials with NRAS Exon 3 Mutation in the inclusion eligibility criteria most commonly target colorectal adenocarcinoma .
Bevacizumab, fluorouracil, leucovorin, and oxaliplatin are the most frequent therapies in trials with NRAS Exon 3 Mutation as an inclusion criteria .
Significance of NRAS Exon 3 Mutation in Diseases
Colorectal Adenocarcinoma +
NRAS is altered in 4.05% of colorectal adenocarcinoma patients with NRAS Exon 3 Mutation present in 2.24% of all colorectal adenocarcinoma patients .
NRAS Exon 3 Mutation is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS Exon 3 Mutation and colorectal adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.